[FK506: an immunosuppressor for the '90's?].

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Medicina clínica (Ed. impresa)

• Publication date

  1993-11-13

• Fields of study

  Medicine

• Identifiers
  PMID 7505871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro.

  1991cited by this paper
• Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.

  1991cited by this paper
• FK 506 in clinical kidney transplantation.

  1991cited by this paper
• Phase II study of FK 506 for allogeneic bone marrow transplantation.

  1991cited by this paper
• Replacement of donor lymphoid tissue in small-bowel transplants.

  1991cited by this paper
• Use of FK 506 in pediatric patients.

  1991cited by this paper
• FK 506 versus cyclosporine in pediatric liver transplantation.

  1991cited by this paper
• Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients.

  1991cited by this paper
• Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

  1991cited by this paper
• FK 506 rescue therapy in liver transplantation: outcome and complications.

  1991cited by this paper
• Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.

  1991cited by this paper
• Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.

  1991cited by this paper
• New horizons in immunosuppression.

  1991cited by this paper
• The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression.

  1991cited by this paper
• FK 506 rescue therapy for refractory acute rejection in five liver recipients.

  1991cited by this paper
• Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

  1991cited by this paper
• Combined liver-islet allotransplantation in man under FK 506.

  1991cited by this paper
• The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation.

  1991cited by this paper
• Early infections in kidney transplant recipients under FK 506.

  1991cited by this paper
• Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.

  1991cited by this paper
• Current status of FK 506 in liver transplantation.

  1991cited by this paper
• Lymphoproliferative disorders after FK 506.

  1991cited by this paper
• The effect of FK 506 on canine pancreatic islet cell function in beagle dogs.

  1991cited by this paper
• Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

  1991cited by this paper
• FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients.

  1991cited by this paper
• Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells.

  1991cited by this paper
• Notes on FK 506.

  1991cited by this paper
• Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients.

  1991cited by this paper
• FK 506: monitoring in plasma or in whole blood?

  1991cited by this paper
• A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

  1991cited by this paper
• Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease.

  1991cited by this paper
• FK506 and rapamycin: novel pharmacological probes of the immune response.

  1991cited by this paper
• A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.

  1991cited by this paper
• Measurement of FK 506 by HPLC and isolation and characterization of its metabolites.

  1991cited by this paper
• THE EFFECT OF GRAFT FUNCTION ON FK506 PLASMA LEVELS, DOSAGES, AND RENAL FUNCTION, WITH PARTICULAR REFERENCE TO THE LIVER

  1991cited by this paper
• THE IMMUNOSUPPRESSIVE ANTAGONISM OF LOW DOSES OF FK506 AND CYCLOSPORINE

  1991cited by this paper
• Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

  1991cited by this paper
• The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation.

  1991cited by this paper
• Kidney transplantation under FK 506 immunosuppression.

  1991cited by this paper
• Compassionate use of FK 506 in pediatric liver transplantation: a pilot study.

  1991cited by this paper
• Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.

  1991cited by this paper
• Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.

  1991cited by this paper
• Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

  1991cited by this paper
• Adverse effects associated with the use of FK 506.

  1991cited by this paper
• Infections in adult liver transplant patients under FK 506 immunosuppression.

  1991cited by this paper
• Lymphoproliferative disorder in a liver transplant patient on FK 506.

  1991cited by this paper
• One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.

  1991cited by this paper
• Distribution of FK 506 in plasma lipoproteins in transplant patients.

  1991cited by this paper
• Pharmacokinetics of FK 506 in transplant patients.

  1991cited by this paper
• Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.

  1991cited by this paper
• CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression.

  1991cited by this paper
• Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.

  1990cited by this paper
• Liver, Kidney, and Thoracic Organ Transplantation Under FK 506

  1990cited by this paper
• Pharmacokinetics of FK 506: preclinical and clinical studies.

  1990cited by this paper
• Early trials with FK 506 as primary treatment in liver transplantation.

  1990cited by this paper
• Infections with FK 506 immunosuppression: preliminary results with primary therapy.

  1990cited by this paper
• Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation.

  1990cited by this paper
• CYCLOSPORINE, FK506, AND RAPAMYCIN: SOME EFFECTS ON EARLY ACTIVATION EVENTS IN SERUM‐FREE, MITOGEN‐STIMULATED MOUSE SPLEEN CELLS

  1990cited by this paper
• Assay of FK 506 in plasma.

  1990cited by this paper
• The effects of FK 506 on renal function after liver transplantation.

  1990cited by this paper
• Oral glucose tolerance test in liver recipients treated with FK 506.

  1990cited by this paper
• Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

  1990cited by this paper
• Kidney transplantation under FK 506.

  1990cited by this paper
• Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.

  1990cited by this paper
• Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical.

  1990cited by this paper
• Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction.

  1990cited by this paper
• FK 506 dosage in human organ transplantation.

  1990cited by this paper
• Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.

  1990cited by this paper
• Immunopharmacology of FK-506.

  1989cited by this paper
• Augmentation of rat liver regeneration by FK 506 compared with cyclosporin.

  1989cited by this paper
• A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase

  1989cited by this paper
• Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.

  1989cited by this paper
• Pharmacology of cyclosporine (sandimmune). I. Introduction.

  1989cited by this paper
• FK 506 for liver, kidney, and pancreas transplantation.

  1989cited by this paper
• Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

  1987cited by this paper
• Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis.

  1987cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

  1987cited by this paper
• Biopharmaceutical aspects of FK-506.

  1987cited by this paper
• Cyclosporin A in patients receiving renal allografts from cadaver donors.

  1978cited by this paper

• [Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases].

  2002cites this paper
• [Tacrolimus (FK506): clinical, pharmacological and analytical aspects].

  1997cites this paper
• Ciclosporina y enfermedad pulmonar alveolointerstícial difusa

  1996cites this paper